At a meeting with analysts and investors at its 2025 Investor Day, members of the leadership team of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will discuss ...

The U.S. dropped to its lowest-ever place on a list of the happiest countries to live in, according to an annual survey ...

For decades, the United States has led the world in pharmaceutical innovation – developing drugs that combat cancer, heart ...

ALZcure is pioneering blockchain-powered funding for Alzheimer's research through Decentralized Science (DeSci). Built on ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

A groundbreaking peer-reviewed Thought Leaders Invited Review article in Brain Medicine (Genomic Press, New York) explores how CD2-associated protein (CD2AP) contributes to Alzheimer's disease (AD), ...

An experimental treatment appears to postpone Alzheimer's symptoms in some people genetically destined to get the disease at ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer’s ...